Ranolazine for Angina in Hypertrophic Cardiomyopathy

Joint Authors

Amin, Akhtar
Kim, Bernard

Source

Case Reports in Cardiology

Issue

Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-2, 2 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2018-04-15

Country of Publication

Egypt

No. of Pages

2

Main Subjects

Diseases

Abstract EN

Ranolazine is an antianginal and works by inhibiting late-sodium current (INaL).

However, its use is limited mostly to patients with coronary artery disease.

However, literature has shown its potential benefit in relieving angina in hypertrophic cardiomyopathy.

Hereby, we discuss two cases where ranolazine led to improvement in angina refractory to beta-blockers.

In conclusion, ranolazine can be considered as a potential antianginal drug in patients with hypertrophic cardiomyopathy refractory to beta-blockers.

American Psychological Association (APA)

Amin, Akhtar& Kim, Bernard. 2018. Ranolazine for Angina in Hypertrophic Cardiomyopathy. Case Reports in Cardiology،Vol. 2018, no. 2018, pp.1-2.
https://search.emarefa.net/detail/BIM-1140994

Modern Language Association (MLA)

Amin, Akhtar& Kim, Bernard. Ranolazine for Angina in Hypertrophic Cardiomyopathy. Case Reports in Cardiology No. 2018 (2018), pp.1-2.
https://search.emarefa.net/detail/BIM-1140994

American Medical Association (AMA)

Amin, Akhtar& Kim, Bernard. Ranolazine for Angina in Hypertrophic Cardiomyopathy. Case Reports in Cardiology. 2018. Vol. 2018, no. 2018, pp.1-2.
https://search.emarefa.net/detail/BIM-1140994

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-1140994